CMPS
Compass Pathways Plc (CMPS)
Healthcare • NASDAQ • $9.91+5.54%
- Symbol
- CMPS
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Price
- $9.91
- Daily Change
- +5.54%
- Market Cap
- $1.34B
- Trailing P/E
- N/A
- Forward P/E
- -8.29
- 52W High
- $10.21
- 52W Low
- $2.25
- Analyst Target
- $21.43
- Dividend Yield
- N/A
- Beta
- 2.40
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Company websiteResearch CMPS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.